Value of direct measurement of active renin concentrations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency
- PMID: 8891554
- DOI: 10.1007/BF02282834
Value of direct measurement of active renin concentrations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Abstract
In congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, measurement of plasma renin activity (PRA) has been the method of choice in diagnosing salt loss and in monitoring adequacy of mineralocorticoid replacement therapy. Due to methodological problems in PRA determinations, direct immunoradiometric assays for the measurement of active renin concentration have been developed. We measured PRA and active renin concentrations simultaneously in 39 patients with CAH (30 salt-wasting, 9 simple virilizing) to evaluate the potential role of this new method in the management of this disease. PRA was determined with an enzymatic assay (sample volume: 2 x 1000 microliters plasma), active renin concentration with a direct immunoradiometric assay (sample volume: 2 x 200 microliters plasma or serum). We found a highly significant correlation between active renin and PRA in our patients (P < 0.001), as previously shown in healthy subjects. Active renin was as reliable as PRA to assess the quality of mineralocorticoid replacement.
Conclusion: In children, active renin determination is preferable to PRA determination because of methodological advantages and a smaller sample volume. It correlates well with PRA and determines the activation of the renin-angiotensin system as precisely as PRA. Active renin determination is useful in the surveillance of mineralocorticoid replacement therapy in CAH.
Similar articles
-
Plasma renin activity and mineralocorticoid replacement therapy in congenital adrenal hyperplasia.Acta Paediatr Acad Sci Hung. 1979;20(2-3):229-35. Acta Paediatr Acad Sci Hung. 1979. PMID: 397714
-
Congenital Adrenal Hyperplasia in Children: The Relationship between Plasma Renin Activity and Hypertension.Iran J Med Sci. 2024 Jun 1;49(6):377-383. doi: 10.30476/ijms.2023.98508.3058. eCollection 2024 Jun. Iran J Med Sci. 2024. PMID: 38952640 Free PMC article.
-
Reinstitution of mineralocorticoid therapy in congenital adrenal hyperplasia. Effects on control and growth.Acta Paediatr Scand. 1981 Mar;70(2):229-33. doi: 10.1111/j.1651-2227.1981.tb05547.x. Acta Paediatr Scand. 1981. PMID: 7015786
-
Mineralocorticoid replacement therapy in salt-wasting congenital adrenal hyperplasia.Clin Endocrinol (Oxf). 2024 Oct;101(4):346-358. doi: 10.1111/cen.14959. Epub 2023 Aug 11. Clin Endocrinol (Oxf). 2024. PMID: 37564007 Review.
-
Hypertension in congenital adrenal hyperplasia and apparent mineralocorticoid excess.Ann N Y Acad Sci. 2002 Sep;970:145-54. doi: 10.1111/j.1749-6632.2002.tb04420.x. Ann N Y Acad Sci. 2002. PMID: 12381549 Review.
Cited by
-
High-dose fludrocortisone therapy was transiently required in a female neonate with 21-hydroxylase deficiency.Clin Pediatr Endocrinol. 2022;31(2):93-97. doi: 10.1297/cpe.2021-0066. Epub 2022 Mar 5. Clin Pediatr Endocrinol. 2022. PMID: 35431448 Free PMC article.
-
The interaction of plasma renin activity and plasma atrial natriuretic peptide in 21-hydroxylase deficiency patients.J Endocrinol Invest. 2005 Apr;28(4):300-4. doi: 10.1007/BF03347194. J Endocrinol Invest. 2005. PMID: 15966501
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials